FACT-Hep
BehavioralPatient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
Other names: The Functional Assessment of Cancer Therapy
NCT Number: NCT03672019
The purpose of this study is to compare the participant's health-related quality of life before and after the biliary drainage procedure. The study will also help us learn whether having a drainage catheter or a stent placed during the procedure makes a difference in the participant's quality of life.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
Other names: The Functional Assessment of Cancer Therapy
Time frame: baseline to week 4 post-procedure
The FACT-Hep minimum score is 0 and the maximum is 180.
Memorial Sloan Kettering Cancer Center
Other
Health-Related Quality of Life in Patients Undergoing Percutaneous Biliary Drainage For Malignant Biliary Obstruction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07559968
Biliary Obstruction, Malignant Biliary Obstruction
Seoul, South Korea
View Trial DetailsNCT07558304
Adenocarcinoma, Bile Duct Diseases
Porto Alegre, Rio Grande do Sul, Brazil
View Trial DetailsNCT07606430
Digestive System Diseases, Digestive System Neoplasms
View Trial DetailsNCT05169398
Malignant Biliary Obstruction
Hong Kong
View Trial Details